- Full Year 2023 Altamira Therapeutics Ltd Earnings Call TranscriptApr 10, 2024$2 (+7.53%)Earnings
- Altamira Therapeutics Ltd to Host Investor & Business Update Call TranscriptDec 11, 2023
- Half Year 2023 Altamira Therapeutics Ltd Earnings Call TranscriptSep 12, 2023$6.39 (-6.03%)Earnings
- Q4 2022 Altamira Therapeutics Ltd Earnings Call TranscriptMay 16, 2023$17.99 (-3.87%)Earnings
- Altamira Therapeutics Ltd Business Update Conference Call TranscriptSep 14, 2022
- Q4 2021 Altamira Therapeutics Ltd Earnings Call TranscriptApr 12, 2022$456 (-31.33%)Earnings
- Altamira Therapeutics Ltd To Discuss Business Update Bentrio TM TranscriptSep 27, 2021
- Auris Medical Holding Ltd Acquires RNA Therapeutics Company - M&A Call TranscriptJun 03, 2021
- Q4 2020 Auris Medical Holding Ltd Earnings Call TranscriptApr 13, 2021$1720Earnings
- Half Year 2020 Auris Medical Holding Ltd Earnings Call TranscriptSep 17, 2020$327.36 (-1.68%)Earnings
- Q4 2019 Auris Medical Holding Ltd Earnings Call TranscriptApr 16, 2020$326.74 (-6.11%)Earnings
- Q2 2019 Auris Medical Holding Ltd Earnings Call TranscriptAug 15, 2019$1076 (-0.74%)Earnings
Altamira Therapeutics Ltd To Discuss Business Update Bentrio TM Transcript
Good morning, and welcome to Altamira Therapeutics Conference Call. On today's call, Thomas Meyer, Altamira's Chairman and Chief Executive Officer, will provide an update on the company's Bentrio program.
During today's call, we will make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial or business performance or the company's strategies or expectations. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements.
These risks and uncertainties include, but are not limited to, the timing and conduct of the company's clinical trials, the clinical utility of its product candidates, the timing or likelihood of regulatory filings and approvals, the company's intellectual property position and its financial position as well as those described in the Risk Factors section
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)